Crystal Pharmatech Expanded its Leadership Team to Keep Management in Pace with Company's Fast Growth
Crystal Pharmatech Co., Ltd has expanded its leadership team with three more executive members: Dr. Shan-Ming Kuang, Dr. Jian Wang and Dr. Lily Li. This reflects Crystal Pharmatech's rapid growth and its well laid-out strategy in keeping its management team in pace with the company's fast growth.
- (1888PressRelease) September 29, 2011 - As Vice President of Technology Development, Dr. Shan-Ming Kuang will lead several departments including preformulation, solid state research, and analytical research. Dr. Jian Wang, in the role of Vice President of Crystallization Development, will head the company's center of excellence for crystallization development. Shan-Ming and Jian will work closely with the company's Chief Scientific Officer Dr. Yanfeng Zhang to oversee all R&D projects and develop core technologies. Dr. Lily Li, as Vice President of Business Development for Asia Pacific, will partner strongly with Dr. Robert Wenslow, Vice President of Business Development in the US and Europe, in establishing collaborations with global pharmaceutical companies and making Crystal Pharmatech a leader in solid state research services.
Before joining Crystal Pharmatech, Dr. Shan-Ming Kuang had spent 10 years at BMS and Roche working on solid state chemistry of pharmaceuticals. He has extensive experience in preformulation development, integrated drug development, and designing/executing crystallizations. Shan-Ming held a Ph.D. in Chemistry from the Chinese Univeristy of Hong Kong and worked as a postdoctoral researcher for 3 years at Purdue University. He has published 36 peer reviewed journal articles, co-authored on 6 patents, and presented at ~20 international conferences. Shan-Ming's strong background in chemistry and extensive experience in solid state research of pharmaceuticals will further enhance Crystal Pharmatech's scientific capabilities in solving challenging problems for its clients.
Dr. Jian Wang has over 20 years R&D and technical consulting experience, serving primarily in the pharmaceutical industry. During her 11 years at Merck, she focused on tackling bottleneck challenges in API process development, and successfully designed and developed numerous API crystallization processes that met or surpassed quality attributes specifications with high productivity. She was an early pioneer and active promoter for applying various process analytical technologies (PAT, e.g., ReactIR, ProcessRaman, FBRM and PVM) in the development and understanding of API crystallization processes. In recent 5-6 years, she worked with Mettler-Toledo Autochem and contributed directly to the development of new generation of PAT tools and new applications of the tools. Jian received her Ph.D. in Chemical Engineering from University of Pittsburgh. She has co-authored 23 peer reviewed journal articles, book chapters, and patents, presented at 15 international conferences, and given numerous trainings and invited presentations on PAT/QbD for API processing. Jian will be instrumental in establishing Crystal Pharmatech's center of excellence for crystallization development.
Dr. Lily Li had her B.S. in chemistry from Peking University and obtained her Ph.D. in Chemisty from Washington University in St. Louis. She worked in Pharmaceutical Research and Development at Merck Research Laboratories for four years and is responsible for providing analytical support for early phase drug product development. During her tenure at Merck, Lily supported several key product value enhancement (PVE) projects and made significant contributions for these projects to reach their critical biocomparison (BC) milestones. Lily's expertise includes analytical method development and validation, release of clinical trial materials, stability evaluations, regulatory filings and technology transfer to commercialization. Lily's wet analytical skill-set, especially in the formulation area, in addition to her strong project management talent will be an integral addition to the team.
"Shan-Ming, Jian and Lily are great additions to our leadership team. Their boarding significantly bolsters our scientific rigor and dedications to innovation." explains Dr. Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd. "We are poised to handle broad solid state issues from our pharmaceutical customers covering all the way from drug discovery to drug supply. Staying on top of innovation while mentoring employees will continue to ensure Crystal Pharmatech remains the leading technology-driven CRO in China."
Since founded in 2010, Crystal Pharmatech has already built strong business relationship with more than 50 global pharmaceutical companies. By providing high quality service with fast turnaround at cost-effective pricing, Crystal Pharmatech is becoming an ideal partner in the field of solid state research for many pharmaceutical companies. The new addition of Drs. Shan-Ming Kuang, Jian Wang and Lily Li in its leadership team shows the clear vision and determination of this young and vibrant company to become a global leader in solid state R&D services for the pharmaceutical industry.
Crystal Pharmatech is a technology-driven CRO that focuses on specialized fields of solid state information and processing for active pharmaceutical ingredients and formulations. It helps its clients to discover and select the optimal solid phase for drug development, design and develop scalable and efficient API crystallization processes to ensure desired quality attributes, and aid in developing the best formulations based on sound scientific understanding. It provides its clients a complete and satisfactory solution to the problem they face instead of merely running experiments and collecting data.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam